¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå
Generic Pharmaceuticals Contract Manufacturing
»óǰÄÚµå : 1774875
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 494 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº 2030³â±îÁö 927¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 732¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 927¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ API´Â CAGR3.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 530¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀǾàǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 5.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 199¾ï ´Þ·¯, Áß±¹Àº CAGR 7.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº 2024³â¿¡ 199¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 187¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.2%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.7%¿Í 3.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.3%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¦³×¸¯ ÀǾàǰ¿¡ ¼öŹÁ¦Á¶ÀÌ ÇʼöÀûÀÎ ÀÌÀ¯´Â?

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº Á¦¾à»çµéÀÌ ÀǾàǰ Á¦Á¶¸¦ Àü¹® ¼öŹÁ¦Á¶±â°ü(CMO)¿¡ À§Å¹ÇÏ´Â °æÇâÀÌ °­È­µÊ¿¡ µû¶ó Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÌ°í °íǰÁúÀÇ Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾à»çµéÀº CMO¸¦ Ȱ¿ëÇÏ¿© »ý»ê È¿À²È­, ±ÔÁ¦ Áؼö, ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϱâ À§ÇØ CMO¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. CMO´Â Á¦Á¦ °³¹ß, ¿ø·áÀǾàǰ(API) Á¦Á¶, Æ÷Àå, ¹°·ù µî ¿£µåÅõ¿£µå ¼­ºñ½º¸¦ Á¦°øÇÔÀ¸·Î½á Á¦¾à ºê·£µå´Â ¿¬±¸, ¸¶ÄÉÆÃ, »óǰȭ¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÊ¿¡ µû¶ó Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±â¾÷µéÀº È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ Á¦Á¶ ¼Ö·ç¼ÇÀ» ã°í ÀÖÀ¸¸ç, CMO´Â FDA, EMA, WHOÀÇ ¿ì¼öÀǾàǰ Á¦Á¶ ¹× ǰÁú°ü¸®±âÁØ(GMP) ¹× ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇϸ鼭 ´ë±Ô¸ð »ý»ê¿¡ ´ëÇÑ ³ôÀº ¼öÁØÀÇ ¿ª·®À» Á¦°øÇÕ´Ï´Ù. °íµµÀÇ »ý»ê ´É·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¹æÃâÁ¦¾î Á¤Á¦, ÁÖ»çÁ¦, ¹ÙÀÌ¿À½Ã¹Ð·¯ µî ÀǾàǰÀÇ Á¦ÇüÀÌ º¹ÀâÇØÁü¿¡ µû¶ó Á¦¾à»çµéÀº º¹ÀâÇÑ Á¦Çü¿¡ ´ëÇÑ ÃÖ÷´Ü ¼³ºñ¿Í Àü¹®¼ºÀ» °®Ãá À§Å¹ »ý»ê¾÷ü¿Í Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ °­È­µÇ°í Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ °æÀïÀÌ Ä¡¿­ÇØÁü¿¡ µû¶ó, ¼öŹÁ¦Á¶Àº Àü ¼¼°è Á¦¾à»çµé¿¡°Ô ÇʼöÀûÀÎ Àü·«ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ¼ö¿ä¸¦ °ßÀÎÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶¿¡ ´ëÇÑ ¼ö¿ä´Â ºñ¿ë È¿À²¼º, ±ÔÁ¦¿¡ ´ëÇÑ Àü¹®¼º, ¼¼°è ½ÃÀå È®´ë¿¡ µû¶ó Å©°Ô Á¿ìµË´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ ÀÇ·áºñ Àý°¨À» À§ÇØ Àú·ÅÇÑ ´ëü ÀǾàǰÀ» ã´Â °¡¿îµ¥, Á¦³×¸¯ ÀǾàǰÀÇ ´ë·® »ý»ê¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. À§Å¹ »ý»ê ¾÷ü´Â ±Ô¸ðÀÇ °æÁ¦¸¦ Ȱ¿ëÇϰí, °ø±Þ¸ÁÀ» ÃÖÀûÈ­Çϰí, Á¦Á¶ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÀÚº» ÁöÃâÀ» ÁÙÀÓÀ¸·Î½á Á¦¾à»çÀÇ Á¦Á¶ ºñ¿ë Àý°¨À» µ½°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ¸·Î ÀÎÇØ ÀÚü Á¦Á¶´Â Á¡Á¡ ´õ º¹ÀâÇϰí ÀÚ¿ø Áý¾àÀûÀ̸ç, CMO´Â ±ÔÁ¦ Áؼö¸¦ Àü¹®À¸·Î Çϸç Á¦³×¸¯ ÀǾàǰÀÌ ±¹Á¦ ǰÁú ¹× ¾ÈÀü Ç¥ÁØÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇÕ´Ï´Ù. ÀÌ´Â ¹Ì±¹, À¯·´, ÀϺ» µî ±ÔÁ¦°¡ ¾ö°ÝÇÑ ½ÃÀå¿¡ ÁøÃâÇÏ´Â ±â¾÷¿¡°Ô ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ¾Ï°ú °°Àº ¸¸¼º Áúȯ Áõ°¡´Â Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖÀ¸¸ç, Á¦¾à»çµéÀº ¼¼°è ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦Á¶ ¾Æ¿ô¼Ò½ÌÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷ÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¼öŹÁ¦Á¶Àº Á¦³×¸¯ ÀǾàǰ Á¦Á¶ÀÇ È¿À²¼º, È®À强, °æÁ¦¼ºÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ÀÇ Ãֽбâ¼ú ¹ßÀüÀº?

ÀǾàǰ ¼öŹÁ¦Á¶ÀÇ ±â¼ú ¹ßÀüÀº È¿À²¼º, ǰÁú, »ý»ê ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ¿¬¼Ó »ý»ê ±â¼úÀÇ Ã¤ÅÃÀº ½Ç½Ã°£ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇϰí, ³¶ºñ¸¦ ÁÙÀ̰í, ¹èÄ¡ °£ ÆíÂ÷¸¦ ÃÖ¼ÒÈ­ÇÔÀ¸·Î½á ÀǾàǰ Á¦Á¶¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº »ý»ê¼ºÀ» Çâ»ó½Ã۰í Á¦³×¸¯ ÀǾàǰ ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇÏ¿© ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ÀǾàǰ Á¦Á¶¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù.

ÀÚµ¿È­ ¹× ÀΰøÁö´É(AI)Àº ǰÁú °ü¸®, ¿¹Áöº¸Àü, °ø±Þ¸Á °ü¸®¸¦ ÃÖÀûÈ­ÇÔÀ¸·Î½á ¼öŹÁ¦Á¶¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, AI ±â¹Ý ºÐ¼®À» ÅëÇØ Á¦Á¶¾÷ü´Â ÀáÀçÀû °áÇÔÀ» °¨ÁöÇϰí, »ý»ê ÀÏÁ¤À» ÃÖÀûÈ­Çϸç, º¸´Ù ³ôÀº Á¤È®µµ·Î ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ª³ëĸ½¶È­ ¹× ¸®Æ÷Á» ¾à¹° Àü´Þ°ú °°Àº ÷´Ü Á¦Çü ±â¼úÀÇ ÅëÇÕÀ» ÅëÇØ CMO´Â Àå½Ã°£ Áö¼ÓÇü ÁÖ»çÁ¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ Æ÷ÇÔÇÑ º¹ÀâÇÑ Á¦³×¸¯ ÀǾàǰÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀǾàǰ ¼öŹÁ¦Á¶ÀÌ µðÁöÅÐÈ­¿Í Çõ½ÅÀ» °è¼Ó ¼ö¿ëÇÔ¿¡ µû¶ó, ¾÷°è´Â È¿À²¼ºÀ» ³ôÀÌ°í ´õ ³ôÀº ǰÁúÀÇ ÀǾàǰÀ» »ý»êÇÒ ¼ö Àִ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Á¦³×¸¯ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀº Àú·ÅÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, º¹ÀâÇÑ ±ÔÁ¦, Á¦Á¶ ±â¼ú ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ºñ¿ë È¿À²ÀûÀÎ ´ëü ÀǾàǰ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Á¦³×¸¯ ÀǾàǰÀÇ »ý»êÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ºê·£µå ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÇ´Â °Íµµ ½ÃÀåÀ» ´õ¿í Ȱ¼ºÈ­½Ã۰í, À§Å¹ »ý»ê¾÷ü°¡ ´ë±Ô¸ð »ý»êÀ» Áö¿øÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÀǾàǰ °ø±Þ¸ÁÀÇ ¼¼°èÈ­¿Í GMP Áؼö ½Ã¼³ÀÇ Çʿ伺À¸·Î ÀÎÇØ Á¦¾à»çµéÀº ±ÔÁ¦ Áؼö ¹× ǰÁú º¸ÁõÀ» Àü¹®À¸·Î ÇÏ´Â CMO¿ÍÀÇ Á¦ÈÞ¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× Ư¼ö Á¦³×¸¯ ÀǾàǰÀ¸·ÎÀÇ ÀüȯÀº º¹ÀâÇÑ Á¦Çü¿¡ ´ëÇÑ ¼öŹÁ¦Á¶ Àü¹® Áö½Ä¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ ±â¼ú, ÀÚµ¿È­, AI ±â¹Ý Á¦Á¶ °øÁ¤ÀÇ µµÀÔÀ¸·Î »ý»ê È¿À²¼ºÀÌ Çâ»óµÇ¾î ¿î¿µ ºñ¿ëÀ» Àý°¨Çϰí ÀǾàǰÀÇ Ç°ÁúÀ» °³¼±ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¦¾à »ê¾÷ÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¼öŹÁ¦Á¶Àº Á¦³×¸¯ Á¦¾à»ç¿¡°Ô È®À强, ºñ¿ë È¿À²¼º, ¼¼°è ½ÃÀå È®´ëÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(API, ÀǾàǰ);ÀǾàǰ(ºê·£µå Á¦³×¸¯, ºñºê·£µå Á¦³×¸¯);Åõ¿© °æ·Î(°æ±¸, ºñ°æ±¸, ±¹¼Ò, ±âŸ Åõ¿© °æ·Î);¿ëµµ(Á¾¾çÇÐ ¿ëµµ, ¸é¿ªÇÐ ¿ëµµ, Ç×´ç´¢º´ ¿ëµµ, ½Å°æÇÐ ¿ëµµ, Ç×ÀÀ°íÁ¦¿ëµµ, ½ÉÀåÇ÷°ü ¿ëµµ, È£Èí±â ¿ëµµ, ÅëÁõ ¿ëµµ, HIV Ç×¹ÙÀÌ·¯½ºÁ¦ ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Generic Pharmaceuticals Contract Manufacturing Market to Reach US$92.7 Billion by 2030

The global market for Generic Pharmaceuticals Contract Manufacturing estimated at US$73.2 Billion in the year 2024, is expected to reach US$92.7 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. API, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$53.0 Billion by the end of the analysis period. Growth in the Drug Product segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.9 Billion While China is Forecast to Grow at 7.2% CAGR

The Generic Pharmaceuticals Contract Manufacturing market in the U.S. is estimated at US$19.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.7 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Generic Pharmaceuticals Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing Becoming Essential for Generic Pharmaceuticals?

The generic pharmaceuticals contract manufacturing market has witnessed significant expansion as pharmaceutical companies increasingly outsource drug production to specialized contract manufacturing organizations (CMOs). With the growing demand for cost-effective and high-quality generic medications, pharmaceutical firms are leveraging CMOs to streamline production, ensure regulatory compliance, and accelerate market entry. Contract manufacturers provide end-to-end services, including formulation development, active pharmaceutical ingredient (API) production, packaging, and logistics, enabling pharmaceutical brands to focus on research, marketing, and commercialization.

The rising patent expirations of blockbuster drugs have fueled the demand for generic pharmaceuticals, driving companies to seek efficient and scalable manufacturing solutions. CMOs offer advanced capabilities in large-scale production while ensuring compliance with Good Manufacturing Practices (GMP) and regulatory standards set by the FDA, EMA, and WHO. Additionally, the increasing complexity of drug formulations, including controlled-release tablets, injectables, and biosimilars, has prompted pharmaceutical firms to partner with contract manufacturers equipped with state-of-the-art facilities and expertise in complex dosage forms. As regulatory scrutiny intensifies and competition in the generic drug market rises, contract manufacturing is becoming an indispensable strategy for pharmaceutical companies worldwide.

Which Factors Are Driving the Demand for Generic Drug Contract Manufacturing?

The demand for generic pharmaceuticals contract manufacturing is largely driven by cost efficiency, regulatory expertise, and global market expansion. With governments and healthcare providers pushing for affordable drug alternatives to reduce healthcare costs, the need for high-volume generic drug production has surged. Contract manufacturers help pharmaceutical companies lower production costs by leveraging economies of scale, optimizing supply chains, and reducing capital expenditures on manufacturing infrastructure.

Additionally, stringent regulatory requirements have made in-house manufacturing increasingly complex and resource-intensive. CMOs specialize in regulatory compliance, ensuring that generic drugs meet international quality and safety standards. This is particularly crucial for companies entering highly regulated markets such as the United States, Europe, and Japan. The increasing prevalence of chronic diseases, including cardiovascular disorders, diabetes, and cancer, has also fueled demand for generic medications, prompting pharmaceutical companies to outsource production to meet rising global needs. As the pharmaceutical industry continues to evolve, contract manufacturing is expected to play a vital role in enhancing efficiency, scalability, and affordability in generic drug production.

What Are the Latest Technological Advancements in Generic Pharmaceuticals Contract Manufacturing?

Technological advancements in pharmaceutical contract manufacturing have significantly improved efficiency, quality, and production capabilities. The adoption of continuous manufacturing technology has revolutionized drug production by enabling real-time monitoring, reducing waste, and minimizing batch-to-batch variability. This innovation enhances productivity and accelerates time-to-market for generic drugs, addressing the growing demand for rapid and cost-effective medication production.

Automation and artificial intelligence (AI) have also transformed contract manufacturing by optimizing quality control, predictive maintenance, and supply chain management. AI-driven analytics help manufacturers detect potential defects, optimize production schedules, and ensure regulatory compliance with greater accuracy. Additionally, the integration of advanced formulation techniques, such as nanoencapsulation and liposomal drug delivery, has enabled CMOs to develop complex generics, including long-acting injectables and biosimilars. As pharmaceutical contract manufacturing continues to embrace digitalization and innovation, the industry is poised for enhanced efficiency and higher-quality drug production.

What Factors Are Fueling the Growth of the Generic Pharmaceuticals Contract Manufacturing Market?

The growth in the generic pharmaceuticals contract manufacturing market is driven by several factors, including the increasing demand for affordable medications, regulatory complexities, and advancements in manufacturing technologies. Governments and healthcare providers worldwide are emphasizing cost-effective drug alternatives, leading to a surge in generic drug production. The rising expiration of branded drug patents has further fueled the market, creating opportunities for contract manufacturers to support large-scale production.

Additionally, the globalization of pharmaceutical supply chains and the need for GMP-compliant facilities have prompted pharmaceutical companies to partner with CMOs specializing in regulatory compliance and quality assurance. The shift toward biosimilars and specialty generics has further increased demand for contract manufacturing expertise in complex formulations. Furthermore, the adoption of digital technologies, automation, and AI-driven manufacturing processes has enhanced production efficiency, reducing operational costs and improving drug quality. As the pharmaceutical landscape continues to evolve, contract manufacturing will remain a key enabler of scalability, cost-effectiveness, and global market expansion for generic drug producers.

SCOPE OF STUDY:

The report analyzes the Generic Pharmaceuticals Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (API, Drug Product); Drug (Branded Generics, Unbranded Generics); Route of Administration (Oral, Parenteral, Topical, Other Route of Administrations); Application (Oncology Application, Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â